Is Everolimus legal in the United Kingdom?

The rapamycin analogue that produced the first credible human geroscience result: improved influenza vaccine response in older adults in a randomised trial.

Everolimus matters to this site for a reason unrelated to its approved uses. It is an approved cancer and transplant drug, and it was also the molecule used for the first randomised trial that took the mTOR longevity hypothesis into humans and got a positive answer.

Mechanism: A rapamycin analogue, or rapalog, that binds FKBP12 and inhibits mechanistic target of rapamycin complex 1. mTORC1 is the central nutrient and growth-factor sensor: when it is active, cells build protein and suppress autophagy, and when it is inhibited, autophagy and stress resistance increase.

Regulatory history: FDA-approved as Afinitor for several cancers and as Zortress for prophylaxis of organ rejection. Not approved for any ageing or immune-ageing indication.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Everolimus at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.